Q4 2024 Zoetis Inc Earnings Call
As president of Investor Relations for Zelle lettuce the.
The presentation materials in additional financial tables are currently posted on the Investor Relations section of the wettest Dot com.
The presentation slides can be managed by you the viewer and will not be forwarded automatically. In addition, a replay of this call will be available approximately two hours. After the conclusion of this call via dial in or on the Investor Relations section of the lettuce Dot com at this time, all participants have been placed in a listen.
Only mode and the floor will be opened for your questions. Following the presentation.
You would like to ask a question at that time. Please press star one on your telephone keypad. If at any point. Your question has been answered you may remove yourself from the queue by pressing star two.
The interest of time, we ask that you limit yourself to one question and then queue up again with any follow ups. Your line will be muted. When you complete your question when posing your question. Please pickup your handset to allow optimal sound quality.
Speaker Change: Lastly, if you should require operator assistance. Please press star zero. It is now my pleasure to turn the floor over to Steve Frank Steve You may begin.
Steve Frank: Thank you operator, good morning, everyone and welcome to the <unk> fourth quarter and full year 2024 earnings call.
Speaker Change: I'm joined today by Kristin Peck, our Chief Executive Officer, and Whitney Joseph Our Chief Financial Officer before we begin I'll remind you that the slides presented on this call are available on the Investor Relations section of our website and that our remarks. Today will include forward looking statements and that actual results could differ materially from those projections.
Speaker Change: For a list and description of certain factors that could cause results to differ I refer you to the forward looking statements in today's press release.
Speaker Change: And our SEC filings, including but not limited to our annual report on Form 10-K, and our reports on Form 10-Q.
Speaker Change: Our remarks today will also include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or U S. GAAP a reconciliation of these non-GAAP financial measures to the most directly comparable U S. GAAP measures is included in the financial tables that accompany our earnings press release and the Companys 8-K.
Speaker Change: Filing data today Thursday February 13, 2024, we also cite operational results, which exclude the impact of foreign exchange with that I will turn the call over to Kristen. Thank you, Steve and good morning, everyone and welcome to our fourth quarter and full year 2024 earnings call today, thanks to that.
Speaker Change: Dedication of our purpose driven colleagues, we reported an excellent full year results in line with the high end of our November guidance.
Speaker Change: We delivered double digit operational revenue growth of 11% highlighting the strength of our strategy and the enduring demand of our brands and our relentless focus on execution drove broad based growth across the business in the U S revenue grew 11% while internationally, we grew 10 <unk>.
Speaker Change: Operationally, marking significant revenue milestone even in a competitive landscape our ability to grow defend and large product across markets drove 14% operational revenue growth in our companion animal portfolio alongside solid 5% operational revenue growth for a lot.
Speaker Change: Stock portfolio.
Speaker Change: Reflecting our commitment to shareholders adjusted net income grew 15% operationally.
Speaker Change: As we look ahead to 2025, we are confident that the drivers of our 2020 for success are sustainable positioning us for continued above market growth in the mid to high single digit range for this year and beyond our confidence is rooted in the diversity of our business model, where multiple growth drivers.
Relations for Delaney
The presentation materials and additional financial tables are currently posted on the Investor Relations section of Zeletis.com.
The presentation slides can be managed by you, the viewer, and will not be forwarded automatically. In addition, a replay of this call will be available approximately two hours after the conclusion of this call via dial-in or on the Investor Relations section of zoedits.com.
Speaker Change: <unk> by scientific innovation, and commercial excellence work together to create and expand market.
Speaker Change: This combination ensures that our market leading franchises deliver long and in some cases decades long growth tailwind with significant room for further expansion.
At this time, all participants have been placed in a listen-only mode and the floor will be open for your questions following the presentation.
Speaker Change: Well, what he will discuss the quarter I want to highlight some of the drivers that will carry us into 2025.
If you would like to ask a question at that time, please press star 1 on your telephone keypad.
Speaker Change: Our global comparative franchise grew 28% operationally on the ear even in niche competition. This success is fueled by the ongoing shift towards triple combination treatments a market that has grown over 40% in the past 12 months.
If at any point your question has been answered, you may remove yourself from the queue by pressing star 2. In the interest of time, we ask that you limit yourself to one question and then queue up again with any follow-ups.
Speaker Change: Your line will be muted when you complete your question. When posing your question, please pick up your handset to allow optimal sound quality. Lastly, if you should require operator assistance, please press star zero. It is now my pleasure to turn the floor over to Steve Frank. Steve, you may begin.
Speaker Change: Currently valued at $2 billion, the global Triple combination market pioneered and led by some purgatory when the U S is projected to more than double to $4 $5 billion by 2028.
Speaker Change: Over 50% of puppies in the U S are now on Triple combination a clear signal of the market's trajectory and veterinarians and pet owners tend to stay with trusted proven solutions underscoring the importance of our three year first mover advantage and triples.
Steve Frank: Thank you, Operator. Good morning, everyone, and welcome to the ZOETA's fourth quarter and full year 2024 earnings call. I am joined today by Kristen Peck, our Chief Executive Officer, and Wetteny Joseph, our Chief Financial Officer.
Steve Frank: Before we begin, I'll remind you that the slides presented on this call are available on the investor relations section of our website, and that our remarks today will include forward-looking statements, and that actual results could differ materially from those projections.
Speaker Change: This dynamic combined with the strength of our diverse portfolio and robust channel strategy, driving higher compliance and increasing total value per patient positions us to continue leading in this critical segment.
Steve Frank: For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statements in today's press release.
Speaker Change: Our osteoarthritis or OA pain franchises, including Labella, and Valencia grew revenue, 80% operationally in 2024.
Steve Frank: and our SEC filings, including but not limited to our annual report on Form 10-K and our reports on Form 10-Q.
Speaker Change: <unk> U S launch is the most successful in our history cementing its blockbuster status in less than four quarters and has quickly become the fourth largest product in our U S pet care portfolio.
Steve Frank: Our remarks today will also include references to certain financial measures which were not prepared in accordance with generally accepted accounting principles or US GAAP.
Speaker Change: As what you mentioned at the Jpmorgan Health Care Conference in January true disruptive scientific innovation, often follows a non linear growth trajectory due to the investment education and market development required to establish an entirely new categories of care, even so innovations like labella our revenue.
Steve Frank: A reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures is included in the financial tables that accompany our earnings press release and the company's 8K filing dated today, Thursday, February 13, 2024.
Steve Frank: We also cite operational results which exclude the impact of foreign exchange.
Speaker Change: I think the treatment paradigm offering new hope for pets and their owners with nearly 25 million doses distributed globally. We have already helped millions of dogs regain mobility and improve their quality of life.
Steve Frank: With that, I will turn the call over to Kristen. Thank you, Steve. And good morning, everyone. And welcome to our fourth quarter and full year 2024 earnings call. Today, thanks to the dedication of our purpose-driven colleagues, we reported an excellent full year result in line with the high end of our November guidance.
Speaker Change: Just as labella is transforming care for dogs Valencia is doing the same for cats now a blockbuster product Celesio has redefined OA pain management, driving a meaningful increase in feline veterinary visits.
Steve Frank: We delivered double-digit operational revenue growth of 11 percent, highlighting the strength of our strategy and the enduring demand of our brand. And our relentless focus on execution drove broad-based growth across the business.
Speaker Change: By encouraging proactive Ter, so lindsay bridging longstanding gap in Medicalization and strengthening the relationship between cat owners and their veterinarian.
Steve Frank: In the U.S., revenue grew 11%, while internationally we grew 10% operationally, marking significant revenue milestones, even in a competitive landscape.
This momentum underscores a significant opportunity to drive sustainable growth in the Underpenetrated feline segment and demand for future therapies and long acting formulations and.
Steve Frank: Our ability to grow, defend, and launch products across markets drove 14% operational revenue growth in our companion animal portfolio, alongside solid 5% operational revenue growth for our livestock portfolio.
Speaker Change: And our key dermatology franchise, we grew revenue, 17% operationally for the year as we shared at J P. Morgan, even with over 25 million dogs treated by our differentiated portfolio to curb its the total addressable market is projected to grow to $2 5 billion by 2028 and 11% CAGR.
Reflecting our
Our commitment to shareholders, adjusted net income grew 15% operationally.
Steve Frank: As we look ahead to 2025, we are confident that the drivers of our 2024 success are sustainable, positioning us for continued above-market growth in the mid-to-high single-digit range for this year and beyond.
Speaker Change: <unk>.
Speaker Change: That's because there are still $20 million worldwide, who remain untreated or under treated with a long runway for growth ahead, I divert safe and effective portfolio supported by strong customer satisfaction brand loyalty and future long acting formulation positions us to lead and expand them.
Steve Frank: Our confidence is rooted in the diversity of our business model, where multiple growth drivers, powered by scientific innovation and commercial excellence, work together to create and expand markets.
Speaker Change: And at the heart of our success is our commitment to living our purpose each day to nurture the world and humankind by advancing care for animals.
Steve Frank: This combination ensures that our market-leading franchises deliver long, and in some cases decades-long, growth tailwinds, with significant room for further expansion.
Speaker Change: That means as customer preferences evolve, ensuring our treatments are available where and when they are needed while always championing the essential role of veterinarian.
Steve Frank: While Wetteny will discuss the quarter, I want to highlight some of the drivers that will carry us into 2025.
This commitment has shaped our omnichannel strategy meeting customers, where they are where they're at the clinic or through alternative channels.
Steve Frank: Our global Simperica franchise grew 28% operationally on the year, even amidst competition.
Speaker Change: As a result compare caitriona apical are the top selling product in U S retail contributing meaningfully higher compliance.
Steve Frank: This success is fueled by the ongoing shift toward triple combination treatment, a market that has grown over 40% in the past 12 months.
Speaker Change: When combining retail and home delivery approximately 20% of our U S. Pet care portfolio flows through alternative channels driving growth and expanding the total market. We expect this trend to continue into 2025.
Steve Frank: Currently valued at $2 billion, the global triple combination market, pioneered and led by some pericatrio in the U.S., is projected to more than double to $4.5 billion by 2028.
Speaker Change: At the same time, we continue to educate veterinarians and pet owners on the benefits and availability of our treatments, helping to drive informed decisions and better health outcomes.
Steve Frank: Over 50% of poppies in the U.S. are now on triple combinations, a clear signal of the market's trajectory. And veterinarians and pet owners tend to stay with trusted, proven solutions, underscoring the importance of our three-year first-mover advantage in triples.
Speaker Change: For the year, our livestock portfolio delivered strong 5% operational revenue growth exceeding our initial expectations of being at the high end of the historical 2% to 4% annual industry growth range. We achieved this result, despite the Q4 divestiture of the medicated feed additives product portfolio.
Steve Frank: This dynamic, combined with the strength of our diverse portfolio and robust channel strategy driving higher compliance and increasing total value for patients, positions us to continue leading in this critical segment.
Speaker Change: And certain water soluble products and related assets.
Steve Frank: Our osteoarthritis or OA pain franchises, including Labrella and Salencia, grew revenue 80% operationally in 2024.
Speaker Change: The divestiture was a strategic move to streamline our portfolio enhance operational focus and prioritize high growth high value areas that along that align with our long term strategy.
Steve Frank: Labrella's U.S. launch is the most successful in our history, cementing its blockbuster status in less than four quarters, and it's quickly become the fourth largest product in our U.S. pet care portfolio.
Speaker Change: And we remain deeply committed to livestock and to continue to lead with innovative vaccines and lifecycle solutions, including antibiotic alternatives and advanced therapies that enhanced disease prevention and supports sustainability aligned with our core capabilities.
Steve Frank: As Wetteny mentioned at the J.P. Morgan Healthcare Conference in January, true disruptive scientific innovation often follows a nonlinear growth trajectory due to the investment, education, and market development required to establish entirely new categories of care.
Speaker Change: As a result of the MFA divestiture, our press release and slides highlight organic operational revenue growth for the full year and fourth quarter, excluding all divested products and adjusted for foreign exchange.
Steve Frank: Even so, innovations like Labrella are revolutionizing the treatment paradigm, offering new hope for pets and their owners. With nearly 25 million doses distributed globally, we have already helped millions of dogs regain mobility and improve their quality of life.
Speaker Change: Based on this and building on the momentum from 2024, we are guiding to a range of 6% to 8% organic operational revenue growth in 2025, and we will continue to provide updates on this metric throughout the year.
Steve Frank: Just as Labrella is transforming care for dogs, Silencia is doing the same for cats. Now a blockbuster product, Silencia has redefined OA pain management, driving a meaningful increase in feline veterinary visits.
Speaker Change: We also expect organic operational growth in adjusted net income in the range of 6% to 8% in 2025 excluding.
Speaker Change: Excluding the impact of interest and taxes, we expect bottom line growth of 8% to 10%, reflecting the strength of our business fundamentals and the robust secular trends driving our industry are strong underlying performance and financial discipline to ensure we remain well positioned to deliver on our value proposition.
Steve Frank: By encouraging proactive care, Salencia is bridging long-standing gaps in medicalization and strengthening the relationship between cat owners and their veterinarians.
Steve Frank: This momentum underscores a significant opportunity to drive sustainable growth in the underpenetrated feline segment and demand for future therapies and long-acting formulations.
Speaker Change: This guidance underscores the strength of our portfolio and commercial engine as we continue to grow our key franchises.
Steve Frank: In our key dermatology franchise, we grew revenue 17% operationally for the year.
Speaker Change: The industry remains essential and resilient driven by strong underlying demand and the indispensable nature of our work.
Steve Frank: As we shared at J.P. Morgan, even with over 25 million dogs treated by our differentiated portfolio to curb itch, the total addressable market is projected to grow to $2.5 billion by 2028, an 11% cater.
Speaker Change: As we look ahead, we will continue balancing strategic investments in innovation and commercial excellence to sustain our track record of profitable growth and generate long term value for our shareholders in.
Steve Frank: That's because there are still 20 million dogs worldwide who remain untreated or undertreated.
Speaker Change: In 2025, our success will be anchored in the same key drivers that have propelled us over the past decade, we operate in highly attractive end markets driven by scientific innovation and market, leading franchises with our global scale, we can launch therapy across geographies and channels, ensuring veterinarians and pet owners.
Steve Frank: With a long runway for growth ahead, a diverse, safe, and effective portfolio supported by strong customer satisfaction, brand loyalty, and future long-acting formulations positions us to lead and expand the market.
Steve Frank: And at the heart of our success is our commitment to living our purpose each day, to nurture the world and humankind by advancing care for animals.
Speaker Change: Access to the best treatments available and while the operating environment evolves every year with new entrants shifting geopolitical dynamics and an evolving regulatory and trade landscape, our agility positions us to navigate these challenges and capitalize on emerging opportunities.
Steve Frank: That means, as customer preferences evolve, ensuring our treatments are available where and when they are needed, while always championing the essential role of veterinarians.
Steve Frank: This commitment has shaped our omni-channel strategy, meeting customers where they are, whether at the clinic or through alternative channels. As a result, Comperica Trio and ApoQuel are the top selling products in U.S. retail, contributing meaningfully higher compliance.
Speaker Change: Our success is driven by the strength of our strategy differentiated execution innovative pipeline our colleagues and culture. This is evident in our R&D engine, where we expect at least one major approval annually over the next several years with multiple potential blockbusters in our pipeline.
Steve Frank: When combining retail and home delivery, approximately 20% of our U.S. pet care portfolio flows through alternative channels, driving growth and expanding the total market. We expect this trend to continue into 2025.
Speaker Change: These innovations will drive durable diversified growth across both companion animals, and livestock reinforcing our commitment to addressing unmet need above all we remain committed to our track record of value creation and delivering performances that outpaces the market positioning <unk> as a trusted leader in <unk>.
Steve Frank: At the same time, we continue to educate veterinarians and pet owners on the benefits and availability of our treatments.
helping to drive informed decisions and better health outcomes.
Speaker Change: Emil Health now and in the future and finally, a sincere. Thank you to our colleagues whose dedication makes these results possible and with that let me turn it over to Whitney.
Steve Frank: For the year, our livestock portfolio delivered strong 5% operational revenue growth, exceeding our initial expectations of being at the high end of the historical 2-4% annual industry growth range.
Whitney Joseph: Thank you Kristen.
Whitney Joseph: Tobacco on Tuesday of mm 124 was an excellent year.
Steve Frank: We achieved this result despite the Q4 divestiture of the medicated feed additives, product portfolio, and certain water-soluble products and related assets.
Whitney Joseph: Our full year performance reflects broad based revenue growth across segments species price and volume.
Whitney Joseph: The foundation of our ability to continually outperformed the animal health industry comes from the diversity of our portfolio and the channels and markets.
Steve Frank: The divestiture was a strategic move to streamline our portfolio, enhance operational focus, and prioritize high-growth, high-value areas that align with our long-term strategy.
Whitney Joseph: We lead.
Whitney Joseph: For the year, we posted revenue of $9 $3 billion growing 8% on a reported basis and 11% operationally with 6% driven by price and 5% from volume.
Steve Frank: and we remain deeply committed to livestock and to continue to lead with innovative vaccines and lifecycle solutions including antibiotic alternatives and advanced therapies that enhance disease prevention and support sustainability aligned with our core capabilities.
Whitney Joseph: We raised our revenue guidance throughout the year and ultimately finished above the high end of our initial range.
Steve Frank: As a result of the MFA divestiture, our press release and slides highlight organic operational revenue growth for the full year and fourth quarter, excluding all divested products and adjusted for foreign exchange.
Adjusted net income grew 10% on a reported basis.
Whitney Joseph: <unk>, 15% operationally to $2 $7 billion.
Whitney Joseph: Global revenue growth was driven by our companion animal portfolio, which grew 14% operationally.
Steve Frank: Based on this and building on the momentum from 2024, we are guiding to a range of 6-8% organic operational revenue growth in 2025 and will continue to provide updates on this metric throughout the year.
Whitney Joseph: Leading the way are some birds eye franchise posted $1 $4 billion in revenue on a year growing 28% operationally.
Whitney Joseph: The broker trio exceeded $1 billion in revenue globally.
Steve Frank: We also expect organic operational growth in adjusted net income in the range of 6 to 8 percent in 2020.
Whitney Joseph: And Pat Cotroneo remains the number one selling canine parasiticide in the U S and the trusted choice for vets and pet owners.
Whitney Joseph: As Christian mentioned Triple combination treatments are the fastest growing segment in animal health and our less than 40% of prescription treatments signaling significant room for continued growth.
Steve Frank: Our strong underlying performance and financial discipline ensure we remain well-positioned to deliver on our value proposition.
Whitney Joseph: You know ethane, we continued to see increased adoption.
Whitney Joseph: Labella influence you reported a combined revenue of $581 million globally for the year growing 80% operationally.
Steve Frank: This guidance underscores the strength of our portfolio and commercial engines as we continue to grow our key franchises.
Whitney Joseph: Over a decade since our first launch our key dermatology franchise posted operational growth of 17%.
Steve Frank: The industry remains essential and resilient, driven by strong underlying demands and the indispensable nature of our work.
Speaker Change: <unk>, one $6 billion in revenue.
Steve Frank: As we look ahead, we will continue balancing strategic investment in innovation and commercial excellence to sustain our track record of profitable growth and generate long-term value for our shareholders.
Speaker Change: We remain steadfast in our confidence to grow the franchise in the face of competition and we delivered strong double digit growth balanced across both abercrombie inside a point.
Speaker Change: We expect continued market expansion driven by higher compliance and new patient growth as we have highlighted that a significant portion of this market remains untreated or under treated.
Steve Frank: In 2025, our success will be anchored in the same key drivers that have propelled us over the past decade.
Steve Frank: We operate in highly attractive end markets driven by scientific innovation and market-leading franchises.
Speaker Change: Lastly, our livestock portfolio also had a strong year with $2 $9 billion in revenue or 5% operational revenue growth driven primarily by price while volume growth.
Steve Frank: With our global scale, we can launch therapies across geographies and channels, ensuring veterinarians and pet owners have access to the best treatments available.
Steve Frank: And while the operating environment evolves every year, with new entrants, shifting geopolitical dynamics, and an evolving regulatory and trade landscape, our agility positions us to navigate these challenges and capitalize on emerging opportunities.
Speaker Change: Winds from the MSA divestiture.
Speaker Change: On an organic operational basis lifestyle grew 7%.
Speaker Change: Moving onto segment performance for the year, both the U S and international segments, So impressive double digit revenue growth.
Steve Frank: Our success is driven by the strength of our strategy, differentiated execution, innovative pipeline, our colleagues, and culture.
Speaker Change: The U S posted $5 $1 billion in revenue growing 11% on the year, while our international segment reported revenue of $4 $1 billion growing 10% operationally for the full year.
Steve Frank: This is evident in our R&D engine, where we expect at least one major approval annually over the next several years with multiple potential blockbusters in our pipeline.
Speaker Change: U S growth was led by our companion animal portfolio, which grew 15% driven by the performance of our some peripheral franchise.
Steve Frank: These innovations will drive durable, diversified growth across both companion animals and livestock, reinforcing our commitment to addressing unmet needs.
Speaker Change: Pain, meds and market expansion across our key dermatology franchise.
Steve Frank: Above all, we remain committed to our track record of value creation and delivering performances that outpace the market, positioning Zoetis as a trusted leader in animal health now and in the future.
Speaker Change: The suburban franchise with nearly $1 billion in revenue growing 26%.
Speaker Change: The broker trio was the primary growth driver with $918 million in sales growing 30%.
Wetteny Joseph: And finally, a sincere thank you to our colleagues whose dedication makes these results possible. And with that, let me turn it over to Wetteny.
Speaker Change: With hardware and pet owner satisfaction cheerios, the leading parasiticide product in the U S.
Speaker Change: Our ability to grow our volume double digits, while simultaneously taking price by being more targeted in our promotions.
Thank you, Kristen.
To echo your enthusiasm, 2024 was an excellent year.
Speaker Change: Our full-year performance reflects world-based revenue growth across segments, species, price, and volume.
Speaker Change: Our first mover advantage.
Speaker Change: <unk> reported $271 million in sales in the U S growing 197%.
Speaker Change: The foundation of our ability to continually outperform the animal health industry comes from the diversity of our portfolio and the channels and markets in which we lead.
Speaker Change: In its first full year in the market the birla generated $201 million in sales and reached blockbuster status in the U S market faster than any product in our history, where it is already the first one choice for severe cases.
Speaker Change: For the year, we posted revenue of $9.3 billion, growing 8% on a reported basis and 11% operationally, with 6% driven by price and 5% from volume.
Speaker Change: With nearly 40% of those suffering from order at some point in their lifestyle. We are confident that luella would be a contributor to growth for years to come.
Speaker Change: We raised our revenue guidance throughout the year and ultimately finished above the high end of our initial range.
Speaker Change: So lithia posted $70 million in new U S revenue for the year growing 58%.
Speaker Change: Adjusted net income grew 10% on a reported basis and 15% operationally to $2.7 billion.
Speaker Change: For the year. So lets you accounted for over 70% of clinic revenue in the fee line or a category and have continued to sustain substantially grow the market since launch.
Speaker Change: Global revenue growth was driven by our companion animal portfolio, which grew 14% operationally.
Speaker Change: Yeah.
Speaker Change: Leading the way, our Simperica franchise posted $1.4 billion in revenue on the year, growing 28% operationally.
Speaker Change: Hey, dermatology had an exceptional year posting growth of 16% on $1 $1 billion in sales.
Empirica Trio exceeded $1 billion in revenue globally.
Speaker Change: As we highlighted there is a substantial population of untreated or undertreated thoughts with derm conditions.
Speaker Change: Sempericatrio remains the number one selling canine parasiticide in the U.S., and a trusted choice for vets and pet owners.
Speaker Change: Our double digit volume growth in key dermatology demonstrates our ability to convert those patients to a differentiated portfolio of treatment options and highlights the continued expansion opportunity in the derm space.
Speaker Change: As Kristen mentioned, triple combination treatments are the fastest growing segment in animal health and are less than 40% of prescription treatments, signaling significant room for continued growth.
Speaker Change: U S livestock business declined 1% on the year due to the MSI divestiture, which closed on October 31.
In O.A. Thain, we continue to see increased adoption.
Excluding the impact of Msas organic operational U S. Livestock growth was 6%, which was driven by improved supply or substitute here.
Speaker Change: Librella and Silencia reported combined revenue of $581 million globally for the year, growing 80% operationally.
Speaker Change: Over a decade since our first launch, our key dermatology franchise posted operational growth of 17%, generating $1.6 billion in revenue.
Speaker Change: Moving onto our international segment revenue grew 5% on a reported basis and 10% operationally for the year.
Speaker Change: International performance was favorably impacted by price increases, especially in high inflationary markets, including Argentina, which contributed more than one 5% of our total company growth for the year.
Speaker Change: We remain steadfast in our confidence to grow the franchise in the face of competition, and we delivered strong double-digit growth balanced across both Apple Coil and Cytopoint.
Speaker Change: We expect continued market expansion, driven by higher compliance and new patient grills, as we have highlighted that a significant portion of this market remains untreated or undertreated.
Speaker Change: Our international companion animal growth was driven by our <unk> key dermatology and OA pain Mab franchises.
Speaker Change: Our <unk> franchise grew 32% operationally to $357 million in international sales.
Speaker Change: Lastly, our lifestyle portfolio also had a strong year, with $2.9 billion in revenue or 5% operational revenue growth, driven primarily by price, while volume growth faced headwinds from the MFA divestiture.
Speaker Change: Performance was driven by some burkha growing 29% operationally to $212 million in sales driven by performance in Latin America and Eastern Europe.
On an organic operational basis, livestock grew 7%.
Speaker Change: Embargo true grew 39% operationally on $145 million in sales driven by key account growth in Europe, DTC and the positive impact of our Q1, China launch.
Speaker Change: Moving on to segment performance for the year, both the U.S. and international segments saw impressive double-digit revenue growth.
Speaker Change: The U.S. posted $5.1 billion in revenue, growing 11% on the year, while our international segment reported revenue of $4.1 billion, growing 10% operationally for the full year.
Speaker Change: Key dermatology posted revenues of $551 million for the year growing 18% operational.
Speaker Change: Performance was driven by Apple grill to new patient growth, especially in Europe.
Speaker Change: U.S. growth was led by our companion animal portfolio, which grew 15%, driven by the performance of our Sympaerica franchise, our O.A. pain mabs, and market expansion across our Keter mythology franchise.
Speaker Change: Sorry to point also contributed with new patient growth and compliance and existing patients.
Speaker Change: Internationally, our OA pain matched with 34% operationally posting $310 million in combined revenue.
Speaker Change: This empirical franchise reached nearly $1 billion in revenue, growing 26%.
Speaker Change: Sales of labella with $246 million internationally growing 33% operational.
Speaker Change: The Pericatrio was the primary growth driver, with $918 million in sales, growing 30%.
Speaker Change: So Lindsay yourselves were $64 million growing 39% on an operational basis.
Speaker Change: With high vet and pet owner satisfaction, Chuyo is the leading parasiticide product in the U.S.
Speaker Change: Our international lifecycle with Twilio <unk> grew 8% operationally to $1 $9 billion in sales for the year with gross growth driven by price as well as strong performance in fish, partially offset by headwinds from swine volumes in China.
Speaker Change: Our ability to grow our volume double digits while simultaneously taking price by being more targeted in our promotions highlights our first mover advantage.
Speaker Change: Our OA Pay and MABs reported $271 million in sales in the U.S., growing 197%.
Speaker Change: Moving onto our Q4 results in the fourth quarter, we posted $2 $3 billion in revenue growing 5% on a reported basis and 6% operationally with 5% driven by price and 1% from volume.
Speaker Change: In its first full year in the market, Lubella generated $201 million in sales and reached blockbuster status in the US market faster than any product in our history, where it is already the first line choice for severe OA cases.
Speaker Change: Excluding the impact of our MFA divestiture, our Q4 organic operational growth was 9% with 4% coming from volume.
Speaker Change: With nearly 40% of dogs suffering from OA at some point in their lifetime, we are confident that Luebela will be a contributor to growth for years to come.
Speaker Change: Adjusted net income of 632 million, those who 11% on a reported basis and 9% operationally.
Speaker Change: Salencia posted $70 million in U.S. revenue for the year, growing 58 percent.
Speaker Change: Revenue in the quarter was driven by our innovative companion animal portfolio.
Speaker Change: For the year, Cilincia accounted for over 70% of clinic revenue in the feline OA category and has continued to substantially grow the market since launch.
Speaker Change: Globally, our synthetic a franchise contributed $324 million growing 21% operational and then our key dermatology franchise posted $417 million or 11% operational growth.
Speaker Change: <unk> contributed revenue of $150 million growing 20% operationally in the quarter.
Speaker Change: Kedar Methodology had an exceptional year, posting growth of 16% on $1.1 billion in sales.
Speaker Change: Our alongside portfolio also contributed operational growth of 1% with $726 million in revenue.
Speaker Change: As we highlighted, there's a substantial population of untreated or under-treated dogs with Durham conditions.
Speaker Change: Lifecycle organic operational growth in the quarter was 8%.
Speaker Change: Our double-digit volume growth in Key Dermatology demonstrates our ability to convert those patients to a differentiated portfolio of treatment options and highlights the continued expansion opportunity in the derm space.
Speaker Change: Our global companion animal diagnostics business grew 10% operationally in the quarter on revenues of $96 million.
Speaker Change: Now, let's move on to our segment results for the quarter.
Speaker Change: U.S. flyspy business declined 1% on the year due to the MFA divestiture which closed on October 31st.
Speaker Change: U S revenue grew 4% in the quarter with companion animal growing 7% and livestock declining 8% due to our MSA divestiture.
Speaker Change: Excluding the impact of MFAs, our organic operational U.S. livestock growth was 6%, which was driven by improved supply of sepsis fuel.
Speaker Change: On an organic operational basis, excluding the MSA impact U S revenue grew 8% in the quarter with 12% lifestyle growth.
Speaker Change: Moving on to our international segment, revenue grew 5% on a rewarded basis and 10% operationally for the year.
Speaker Change: In companion Animal U S performance was driven by growth in our <unk> key dermatology and OA pain franchises.
International performance was favorably impacted by price increases, especially in
Speaker Change: Pet owners continue to seek the highest standard of care offered by our innovative products and vet clinic revenue remained healthy growing 7% on average spend per visit basis. Despite declining visits overall.
Speaker Change: high inflationary markets, including Argentina, which contributed more than 1.5% to our total company growth for the year.
Speaker Change: Our international companion animal group was driven by Simparica, Kedermatology, and O.A.P.M.A.B. franchises.
Speaker Change: Our mats are driving higher therapeutic visits.
Speaker Change: Our <unk> franchise posted U S growth of 17% with $240 million in revenue for the fourth quarter led by <unk> trio.
Speaker Change: Our Semperica franchise grew 32% operationally to $357 million in international sales.
Speaker Change: As Christa highlighted we expect the triple combination parasiticide market to more than double by 2028 and higher Triple combo share amongst puppies is a key indicator of where the market is growing.
Speaker Change: Performance was driven by Simperica, growing 29% operationally to $212 million in sales, driven by performance in Latin America and Eastern Europe.
Speaker Change: Our key dermatology franchise grew 7% in the quarter generating $270 million in revenue despite.
Speaker Change: and Perica Trio with 39% operation only on $145 million in sales, driven by key account growth in Europe, DTC and the positive impact of our Q1 China launch.
Speaker Change: <unk> stocking headwind from the apical of trouble launch last year.
Speaker Change: During visits were 4% in the quarter, highlighting the willingness of pet owners to treat itch.
Speaker Change: Key Dermatology posted revenues of $551 million for the year, growing 18% operationally.
Speaker Change: <unk> was the largest driver of growth driven by preference for injectable treatments.
Speaker Change: Performance was driven by Apple Quill through new patient growth, especially in Europe.
Speaker Change: <unk> growth continues to be driven by expansion of Africa, chewable benefiting from increased conversion and compliance driven by alternative channels.
Speaker Change: Cytopoint also contributed with new patient growth and compliance in existing patients.
Speaker Change: Internationally, our OAP maps grew 34% operationally, boasting $310 million in combined revenue.
Speaker Change: Oh, Hey, Matt the Kweilin Celesio posted a combined $71 million in U S sales in Q4 growing 22%.
Sales of Lubella were $246 million internationally, growing 33% operationally.
Speaker Change: Our growth in the quarter is reflective of headwinds from initial clinic stocking in Q4 of 2023.
Speaker Change: Valencia sales were $64 million, growing 39% on an operational basis.
Speaker Change: Labella now entering its second year in the market generated $53 million growing 21% on the quarter and reaching more than $1 2 million patients. We remain confident that the market opportunity is significant.
Speaker Change: Our international livestock portfolio grew 8% operationally to $1.9 billion in sales for the year, with growth driven by price as well as strong performance in fish, partially offset by headwinds from swine volumes in China.
Speaker Change: Pain related vet visits increased 16% in the fourth quarter highlighting the demand that has propelled labella to the fourth largest products in our U S business and the most successful launch in animal health history.
Speaker Change: Moving on to our Q4 results, in the fourth quarter, we posted $2.3 billion in revenue, growing 5% on a reported basis and 6% operationally, with 5% driven by price and 1% from volume.
Speaker Change: Organic operational growth in U S. Livestock of 12% was primarily driven by the timing of supplier subsidies and volume growth in Jackson.
Speaker Change: Excluding the impact of our MFA divestiture, our Q4 organic operational growth was 9% with 4% coming from volume.
Speaker Change: Moving on to our international segment for the quarter revenue grew 6% on a reported basis and 10% excluding the impact of foreign exchange.
Speaker Change: Adjusted net income of $632 million, grew 11% on a reported basis, and 9% operationally.
Speaker Change: Companion animal grew 13% operationally and livestock grew 6% operational.
Speaker Change: Revenue in the quarter was driven by our innovative companion animal portfolio.
Speaker Change: The MSI divestiture did not have a material impact on our international organic operational growth.
Globally, our Simperica franchise contributed $324 million, growing 21% operationally.
Speaker Change: Our international companion animal portfolio growth was driven by our key dermatology products are superior to franchise and our OA pain maps.
Speaker Change: Our Key Dermatology franchise posted $417 million, or 11% operational growth, and our OA-PAY maps contributed revenue of $150 million, going 20% operationally in the quarter.
Speaker Change: Our key dermatology products grew 19% operationally with sales of $147 million in the quarter.
Speaker Change: Growth in key dermatology was driven by new patients and increase share for both Africa inside a point driven by field force execution and brand marketing campaigns.
Speaker Change: Our livestock portfolio also contributed operational growth of 1% with $726 million in revenue. Livestock organic operational growth in the quarter was 8%.
Speaker Change: Preference will <unk> continues to increase with conversion to <unk> in Europe now at 50%.
Speaker Change: Our Global Companion Animal Diagnostics Business grew 10% operationally in the quarter on revenues of $96 million.
Speaker Change: We saw 32% operational growth in Austin protocol franchise internationally with revenue of $84 million on the quarter.
Speaker Change: Now, let's move on to our segment results for the quarter.
Speaker Change: U.S. revenue grew 4% in the quarter, with companion animal growing 7% and livestock declining 8% due to our MFA divestiture.
Speaker Change: <unk> was the main growth driver growing 33% operationally at $53 million in revenues.
Speaker Change: On an organic operational basis, excluding the MSA impact, U.S. revenue grew 8% in the quarter with 12% livestock growth.
Speaker Change: The <unk> with 30% operationally with $31 million in revenues.
Speaker Change: Internationally, our <unk> grew 18% operationally posting $79 million in combined revenue.
Speaker Change: In Comparin' Animal, U.S. performance was driven by growth in our Simperica, Kedermatology, and OAPA franchises.
Speaker Change: The boiler posted sales of $62 million in the quarter growing 15% operational.
Speaker Change: Pet owners continue to seek the higher standard of care offered by our innovative products. And vet clinic revenue remains healthy, going 7% on an average spend per visit basis, despite declining visits overall.
Speaker Change: We see continued growth in prescribing rates and penetration and reorder rates remain high.
Speaker Change: So lindsay a growth of 28% operationally on $17 million of sales is driven by increases in both returning and new OA patients.
Our maths are driving higher therapeutic visits.
Speaker Change: Our Semperica franchise posted U.S. growth of 17% with $240 million in revenue for the fourth quarter, led by Semperica Trio.
Speaker Change: International livestock reported sales of $477 million in the fourth quarter growing 6% operational.
Speaker Change: Growth came primarily from price and hyper inflationary markets and in cattle.
Speaker Change: As Kristen highlighted, we expect the triple combination parasiticide market to more than double by 2028, and higher triple combo share amongst puppies is a key indicator of where the market is going.
Speaker Change: Moving down the P&L.
Speaker Change: Full year adjusted gross margins of 77% grew 50 basis points on a reported basis.
Speaker Change: Our Key Dermatology franchise grew 7% in the quarter, generating $270 million in revenue, despite ClinX stocking Headwind from the Apricot Truable launch last year.
Speaker Change: Foreign exchange had an unfavorable impact of 40 basis points.
Speaker Change: Excluding FX, we saw higher margins due to price and favorable mix, partially offset by higher manufacturing costs.
Speaker Change: Their visits were 4% in the quarter, highlighting the willingness of pet owners to treat each.
Speaker Change: Adjusted operating expenses increased 10% operationally for the year.
Speaker Change: Cytopoint was the largest driver of growth, driven by preference for injectable treatments.
Speaker Change: Growth was driven primarily by SG&A increases of 9% operationally largely due to higher compensation related expenses due in part to company performance.
Speaker Change: Apricot growth continues to be driven by expansion of apricot chewable benefiting from increased conversion and compliance driven by alternative channels.
Speaker Change: Full year G&A growth is it inclusive of fourth Q4 growth of 11% operational reflective of the acceleration of certain demand generating activities into Q4 of 2024.
Speaker Change: Our OFA maps, La Buella and Salencia, posted a combined $71 million in U.S. sales in Q4, growing 22%.
Speaker Change: R&D spend grew 12% operationally for the year on higher compensation related expenses due to company performance and increases in project spend related to internal portfolio advancement.
Speaker Change: Our growth in the quarter is reflective of headwinds from initial clinic stocking in Q4 of 2023.
Speaker Change: Labrella, now entering its second year in the market, generated $53 million, growing 21% on the border and reaching more than 1.2 million patients.
Speaker Change: Adjusted net income grew faster than revenue at 15% operational.
Speaker Change: Adjusted diluted EPS grew 17% operationally for the year.
We remain confident that the market opportunity is significant.
Speaker Change: We remain committed to reinvesting in the business, while returning capital to shareholders.
Speaker Change: Pain-related vet visits increased 16% in the fourth quarter, highlighting the demand that has propelled Labrella to the fourth-largest product in our U.S. business and the most successful launch in animal health history.
Speaker Change: In 2024, we repurchased one 9 billion shares.
Speaker Change: Shares the most in our history.
Speaker Change: We also reaffirmed our commitment to buying back shares in August when our board approved a new multi year $6 billion share repurchase program.
Speaker Change: Organic operational growth in U.S. livestock of 12% was primarily driven by the timing of supply of septic fuel and volume growth in Jackson.
Speaker Change: Additionally, we increased our dividend rate, 15% during the year, while distributing $786 million back to shareholders.
Speaker Change: Moving on to our international segment for the quarter, revenue grew 6% on a reported basis and 10% excluding the impact of foreign exchange.
Speaker Change: In total we returned over $2 6 billion to shareholders in 2024, an increase of over $800 million versus the prior year.
Companion animal grew 13% operationally, and livestock grew 6% operationally.
Speaker Change: Now moving on to our guidance for the full year 2025.
Speaker Change: The MFA divestiture did not have a material impact on our international organic operational growth.
Speaker Change: The strengthening U S. Dollar throughout 2024 has been a headwind to our reported revenue and adjusted net income projections.
Speaker Change: Our international companion animal portfolio, Gwilf, was driven by our key dermatology products, our Simperica franchise, and our OA pain maps.
Speaker Change: As a reminder, we do not forecast foreign exchange and our guidance reflects rates as of late January.
Speaker Change: Our Key Dermatology products grew 19% operationally, with sales of $147 million in the quarter.
Speaker Change: Our 2025 guidance reflects foreign exchange headwinds of approximately $250 million to revenue and $50 million to adjusted net income versus 2024.
Speaker Change: Growth in Ketermatology was driven by new patients and increased share for both Apocryl and Cytopoint, driven by field force execution and brand marketing campaigns.
Speaker Change: For 2025, we are projecting revenue between $9 225, and $9 $3 75 billion, representing an organic operational growth range of 6% to 8% with growth across both price and volume.
Speaker Change: Preference for chewables continues to increase, with conversion to apical chewable in Europe now at 50 percent.
Speaker Change: We expect our performance will be driven by our companion animal business with broad based growth across America, dermatology and OA pain franchises.
Speaker Change: Semperica was the main growth driver, growing 33% operationally on $53 million in revenues.
Speaker Change: We are projecting these combined innovative franchises to grow double digits in 2025.
Speaker Change: and Parker Trio with 30% operation only with 31 million dollars in revenues.
Speaker Change: Our growth estimates include a range of assumptions for new market entrants and conditions across our business.
Speaker Change: Internationally, our OFA MAPS grew 18% operationally, boasting $79 million in combined revenue.
Speaker Change: As a reminder, our guidance does not include products that have not yet been approved.
Speaker Change: Librela posted sales of $62 million in the quarter, growing 15% operationally.
Speaker Change: Additionally guidance does not account for the impact of recent and potential policy changes, including tariffs tax reform or other regulatory changes.
Speaker Change: We see continuous growth in prescribing rates, and penetration and reorder rates remain high.
Speaker Change: While livestock Twenty's going forward growth was favorably impacted by tailwind from price, particularly in high inflationary markets, including Argentina.
Speaker Change: So, lengthier growth of 28% operationally on $17 million of sales is driven by increases in both returning and new OOA patients.
Speaker Change: Those impacts normalize as the year progressed, and we do not expect similar tailwind for 2025.
Speaker Change: International Life Stock reported sales of 477 million dollars in the fourth quarter, growing 6% operationally.
Speaker Change: Additionally, our reported growth for livestock will be negatively impacted by our MFA divestiture, we will continue to provide organic operational comparisons throughout the year to normalize for this impact.
Speaker Change: Growth came primarily from price in hyperinflationary markets and in cattle.
Moving down the P&L.
Speaker Change: Full-year adjusted gross margins of 70.7% grew 50 basis points on a reported basis.
Speaker Change: We expect our organic operational lifestyle growth to be in line with the livestock industry growth for the year.
Speaker Change: for an exchange had an unfavorable impact of 40 basis points.
Speaker Change: Now moving onto the rest of the P&L.
Speaker Change: Excluding FX, we saw higher margins due to price and favorable mix partially offset by higher manufacturing costs.
Speaker Change: Adjusted cost of sales as a percentage of revenue is expected to be approximately 28%.
Speaker Change: Our expected margin improvement is driven by favorable product mix aided by our MFA divestiture.
Adjusted operating expenses increased 10% operationally for the year.
Speaker Change: Our growth estimates include a range of assumptions for new market entrants and conditions across our business.
Speaker Change: Growth was driven primarily by SG&A increases of 9% operationally, largely due to higher competition related expenses, due in part to company performance.
Speaker Change: This improvement is partially offset by foreign exchange impacts within our supply chain.
Speaker Change: As a reminder, our guidance does not include products that have not yet been approved.
Speaker Change: Adjusted SG&A expenses for the year are expected to be between two three and $2 35 billion.
Speaker Change: Additionally guidance does not account for the impact of recent and potential policy changes, including tariffs tax reform or other regulatory changes.
Speaker Change: Full US DNA growth is inclusive of Q4 growth of 11% operationally, reflective of the acceleration of certain demand-generating activities into Q4 of 2024.
Speaker Change: This change is reflective of a normalization of compensation increases tied to 2020 for performance as well as the acceleration of certain demand generating activities into Q4 of the prior year.
Speaker Change: For livestock Twenty's going forward growth was favorably impacted by tailwind from price, particularly in high inflationary markets, including Argentina.
Speaker Change: R&D spend grew 12% operationally for the year on higher compensation related expenses due to company performance and increase.
Speaker Change: Adjusted R&D expenses for 2025 is expected to be between 680 and $690 million.
Speaker Change: Those impacts normalize as the year progressed, and we do not expect similar tailwind for 2025.
in project span related to internal portfolio advancement.
Speaker Change: We are coming off a multiyear cycle of R&D investment at a pace greater than revenue growth with the output of those investments reflected in the portfolio progress we disclosed at the JP Morgan Conference last month.
Adjusted net income grew faster than revenue at 15% operationally.
Additionally, our reported growth for livestock will be negatively impacted by our MFA divestiture, we will continue to provide organic operational comparisons throughout the year to normalize for this impact.
Adjusted diluted EPS grew 17% operationally for the year.
Speaker Change: We remain committed to reinvesting in the business while returning capital to shareholders.
Speaker Change: Adjusted interest expense and other income deductions is expected to be approximately $200 million.
Speaker Change: We expect our organic operational lifestyle growth to be in line with the livestock industry growth for the year.
Speaker Change: Our adjusted effective tax rate for 2025 is expected to be approximately 21%.
Speaker Change: Now moving onto the rest of the P&L.
Speaker Change: We also reaffirmed our commitment to buying back shares in August when our board approved a new multi-year $6 billion dollar share repurchase program.
Speaker Change: Adjusted cost of sales as a percentage of revenue is expected to be approximately 28%.
Speaker Change: Adjusted net income is expected to be in the range of $2 seven to $2 75 billion.
Speaker Change: Our expected margin improvement is driven by favorable product mix aided by our MFA divestiture.
Speaker Change: Additionally, we increased our dividend rate 15% during the year while distributing $786 million back to shareholders.
Speaker Change: Representing growth of 2% to 4% on an operational basis, and 6% to 8% on an organic operational basis.
Speaker Change: This improvement is partially offset by foreign exchange impacts within our supply chain.
Speaker Change: In total, we returned over $2.6 billion to shareholders in 2024, an increase of over $800 million versus the prior year.
Speaker Change: Our growth of adjusted net income is impacted by net interest headwinds due to lowering rates uninvested cash versus prior years.
Speaker Change: Adjusted SG&A expenses for the year are expected to be between two three and $2 $35 billion.
Speaker Change: Now, moving on to our guidance for the full year 2025.
Additionally, while our adjusted effective tax rate guidance for 2025 is within our historical range. It is at the higher end of the range due to higher taxes on foreign earnings.
Speaker Change: This change is reflective of a normalization of compensation increases tied to 2020 for performance as well as the acceleration of certain demand generating activities into Q4 of the prior year.
Speaker Change: The strengthening U.S. dollar throughout 2024 has been a headwind to our reported revenue and adjusted net income projections.
Speaker Change: As a reminder, we do not forecast foreign exchange, and our guidance reflects rates as of late January.
Speaker Change: Our organic operational adjusted net income growth is expected to be 6% to 8%. If we further exclude the impact of interest and taxes, our bottomline growth is expected to be between 8% and 10%.
Adjusted R&D expenses for 2025 is expected to be between 680 and $690 million.
Speaker Change: Our 2025 guidance reflects foreign exchange headwinds of approximately $250 million to revenue and $50 million to adjusted net income versus 2024.
Speaker Change: We are coming off a multi year cycle of R&D investments at a pace greater than revenue growth with the output of those investments reflected in the portfolio progress we disclosed at the Jpmorgan conference last month.
Speaker Change: Lastly, we expect adjusted diluted EPS to be in the range of $6 to $6 <unk>.
Speaker Change: And reported diluted EPS to be in the range of $5 70.
Speaker Change: Adjusted interest expense and other income deductions is expected to be approximately $200 million.
Speaker Change: To $5 80.
Speaker Change: Our EPS projections are based on current share count and do not consider the future impact of our ongoing share repurchase program.
Speaker Change: Our adjusted effective tax rate for 2025 is expected to be approximately 21%.
Speaker Change: In closing 2020 for success was built upon the strength of our broad portfolio and our purpose driven colleagues.
Speaker Change: Adjusted net income is expected to be in the range of $2 seven to $2 75 billion.
Speaker Change: Presenting a growth of 2% to 4% on an operational basis, and 6% to 8% on an organic operational basis.
Speaker Change: Our success across key brands geographies and channels is the foundation, which gives us confidence in our ability to sustain above market growth this year and into the future.
Speaker Change: Our growth of adjusted net income is impacted by net interest headwinds due to lowering rates uninvested cash versus prior years.
Speaker Change: Now I'll hand things over to the operator to open the line for your questions.
Speaker Change: Additionally, while our adjusted effective tax rate guidance for 2025 is within our historical range. It is at the higher end of the range due to higher taxes on foreign earnings.
Speaker Change: Later.
Speaker Change: Thank you and at this time, if you would like to ask a question. Please press star one on your telephone keypad may withdraw your question at any time that pricing start to you. Once again that is star one we'll take our first question from Michael <unk> with Bank of America. Please go ahead.
Speaker Change: Our organic operational adjusted net income growth is expected to be 6% to 8% if.
Speaker Change: If we further exclude the impact of interest and taxes, our bottomline growth is expected to be between 8% and 10%.
Speaker Change: Great. Thanks for taking the question guys I've got two related ones I'll sneak them in together. So first wasn't in your prepared remarks, you sort of said you have a range of assumptions for new market entrants and market conditions and the guide I wanted to dive into that there's.
Speaker Change: Lastly, we expect adjusted diluted EPS to be in the range of $6 to $6 10, and reported diluted EPS to be in the range of $5 70.
Speaker Change: Theres a lot of competition in the market. This year that you already have one on the market for derm, There's a second major applicable competitor expected this summer.
Speaker Change: To $5 80.
Speaker Change: Our EPS projections are based on current share count and do not consider the future impact of our ongoing share repurchase program.
Speaker Change: So explicitly could you sort of walk us through what you're factoring into the guide.
Speaker Change: Whether it's in terms of color for growth for those products.
Speaker Change: In closing 2020 for success was built upon the strength of our broad portfolio and our purpose driven colleagues.
Speaker Change: Give some broad comments on growth expectations, but also just sort of incremental headwinds from competition and how that could play out and then tied to that I.
Speaker Change: Our success across key brands geographies and channels is the foundation, which gives us confidence in our ability to sustain above market growth this year and into the future.
I guess.
Speaker Change: Are you.
Speaker Change: Are you taking on any incremental investments to support your major brands Derm Commvault cares set asides in terms of go to market strategy commercial efforts, maybe in terms of bundling products together alternative channels or sort of how are you adjusting that in the face of some of that growing competition.
Speaker Change: Now I'll hand things over to the operator to open the line for your questions.
Operator.
Speaker Change: Thank you and at this time, if you would like to ask a question. Please press star one on your telephone keypad.
Speaker Change: Withdraw your question at any time that pricing start to once again that is star one we will take our first question from Michael <unk> with Bank of America. Please go ahead.
Speaker Change: Yes.
Mike: Thank you Mike.
Speaker Change: To take the question on competition look first of all we have delivered an outstanding 2024 with 11% growth.
Speaker Change: Great. Thanks for taking the question guys I've got two related ones I'll sneak them in together.
Speaker Change: Operationally at revenue of 15% of just net income if you look across our key major franchises, we delivered double digit growth across all three of those major franchises in Durham.
Speaker Change: So first one in your prepared remarks, you sort of said you have a range of assumptions for new market entrants and market conditions in the guide I wanted to dive into that.
Speaker Change: In the context of derm more than a decade, and we're delivering 17% operational growth include as we usually do with our guidance as we started the year, we take into consideration a number of factors we have multiple sources of growth.
Speaker Change: There's a lot of competition in the market. This year you already have one on the market for derm, There's a second major apical competitor expected this summer.
Speaker Change: So explicitly could you sort of walk us through what you're factoring into the guide.
Speaker Change: And while we're not providing individual product guidance, what we're saying is these three major franchise areas, we expect to drive double digit growth for us in 2025, and we see the underlying trends that drove our performance in 2024 carriers into 2025 with momentum now.
Speaker Change: Whether it's in terms of color for growth for those products.
Speaker Change: Kind of just give some broad comments on growth expectations, but also just sort of incremental headwinds from competition and how that could play out and then tied to that I.
Speaker Change: I guess.
Speaker Change: Now in terms of competition, we are factoring in various scenarios in terms of where competition might look like in the case of <unk>, we expect those that to be in the second half of the year.
Speaker Change: Are you.
Speaker Change: Are you taking on any incremental investments to support your major brands Derm combo set asides in terms of go to market strategy commercial efforts, maybe in terms of bundling products together alternative channels or sort of how are you adjusting that in the face of some of the growing competition. Thank you.
Speaker Change: Again, not providing individual guidance on derm, specifically, but certainly long term.
Speaker Change: We expect to continue to drive substantial growth in these categories. If you look at <unk>. For example, we're estimating 20 million dogs globally that are not treated or undertreated, we're treating about $12 million today with ethical insider point Theres still 7 million. There are on other therapies like steroids. For example, another 13 that are not getting your procedure.
Speaker Change: Thank you Mike.
Speaker Change: Happy to take the question on competition look first of all we have delivered an outstanding 2024 with 11% growth.
Speaker Change: Our operational yet revenue and 15% of adjusted net income if you look across our key major franchises, we delivered double digit growth across all three of those major franchises in Durham.
Speaker Change: Joe So clearly the opportunity that remains here is actually pretty vast and that gives us a lot of confidence in terms of our long term growth.
Speaker Change: And the content.
Speaker Change: More than a decade, and we're delivering 17% operational growth include as we usually do with our guidance as we started the year. We took into consideration a number of factors. We have multiple sources of growth and while we are not providing individual product guidance. What we're saying is these three major franchise areas, we expect to drive double digit growth was in <unk>.
Speaker Change: In terms of investments look I think you've seen us do this quite.
Speaker Change: Quite well at the same time, we are leveraging other investments we've made in our field force et cetera to drive operational leverage through the P&L in the case of putting support behind our key brands, whether it's DTC, whether it's education veterinarians et cetera, that's something we have demonstrated an ability to do and they have.
Speaker Change: 25, and we see the underlying trends that drove our performance in 2024 carriers into 2025 with momentum.
Speaker Change: Great returns for us when we do that we have.
Speaker Change: Significant measurements that shows that those are areas that we are factoring into our guidance from a spend standpoint.
Speaker Change: Now in terms of competition, we are factoring in various scenarios in terms of what competition might look like in the case of <unk>, we expect those that to be in the second half of the year again.
Speaker Change: Thank you we'll take our next question from Erin Wright with Morgan Stanley. Please go ahead.
Speaker Change: Again, not providing individual guidance on on derm, specifically, but certainly long term.
Erin Wright: Great. Thanks, I wanted to get a little bit more on to Libra logic can you speak to how that's are responding following that letter in LIBOR teams like is that help them in terms of understanding how to prescribe and you mentioned, it's not linear but how do we think about USA birla contributions in terms of what's embedded in the guide for 2012.
Speaker Change: We expect to continue to drive substantial growth in these categories. If you look at <unk>. For example, we're estimating 20 million dogs dogs globally that are not treated or undertreated, we're treating about $12 million today with ethical insider point, there's still 7 million. There are on other therapies like steroids. For example, another 13 that are not getting your procedure.
Speaker Change: By then just to confirm the long acting and other pipeline product or not.
Erin Wright: Got it in your guidance.
Joe So clearly the opportunity that remains here is actually pretty vast and that gives us a lot of confidence in terms of long term growth.
Erin Wright: For this year and then just the last one just on the margin improvement year to year. In 2025 can you talk a little bit about what's driving that in terms of the mix shift with the MSI divestiture or anything else to call out.
Speaker Change: In terms of investments look I think you've seen us do this quite.
Speaker Change: Quite well at the same time, we are leveraging other investments we made in our field force et cetera to drive operational leverage through the P&L in the case of putting support behind our key brands, whether it's DTC, whether it's education veterinarians et cetera, that's something we have demonstrated an ability to do and they have.
Erin Wright: Thanks, Aaron I'll take labella questions and let me take the margin question a quick answer no no new products are included along I think are not included in the guidance.
Erin Wright: I think let me manage.
Speaker Change: I mentioned look we're really pleased with the launch of labella with $581 million in sales across labella, Insulins hear an 80% growth on the year.
Speaker Change: <unk> returns for us when we do that we have significant.
Speaker Change: Significant measurements that shows that those are areas that we are factoring into our guidance from a spend standpoint.
Speaker Change: Really pleased it is the most successful launch in history. As we've mentioned it's also now the fourth largest product for us the wettest with 25 million doses.
Speaker Change: Thank you we'll take our next question from Erin Wright with Morgan Stanley. Please go ahead.
Speaker Change: 40% of dogs suffer from OE and what we really see as we look forward is continued growth in this category. We did get that letter, which helped that to understand what the update in adverse events were using real world data and we obviously.
Erin Wright: Great. Thanks.
Erin Wright: I wanted to get a little bit more on <unk> can you speak to how that's are responding following that letter and label change like that help them in terms of understanding how to prescribe them.
Erin Wright: And you mentioned, it's not linear but how do we think about U S. Like rattler contributions in terms of what's embedded in the guide for 2025, and just to confirm the long acting <unk> and other pipeline product or not.
Speaker Change: Showed you the label that we implemented based on that and I think that really underscores our commitment for transparency, which we've been doing all along with regard to the adverse events.
Erin Wright: Got it in your guidance.
Speaker Change: Would highlight that there were no contraindications and no warnings and no precautions in that label, but we were really pleased to be able to share that with veterinarians consistent with our purpose and consistent with our commitment anything veterinarians have found that quite helpful that label as we had mentioned to you. Many times is we expected it to be consistent with our label and international where we continue.
Erin Wright: For this year and then just a last one just on the margin improvement year to year. In 2025 can you talk a little bit about what's driving that in terms of the mix shift with the MSA divestiture or anything else to call out.
Erin Wright: Thanks, Erinn I'll take labella questions and let me take the margin question a quick answer no no new products are included along I think are not included in the guidance.
Speaker Change: To be driving growth as you saw throughout 2024, so the U S label looks largely like a label in Europe, or Canada, and we really look forward to continuing to grow. This franchise. What do you do you want to take the second question on margin sure before I get to the margin maybe just one more point I'll make on the <unk> you asked about how we factored that into our guidance clearly.
Erin Wright: I think let me managed.
Speaker Change: What I mentioned look we're really pleased with the launch of labella with $581 million in sales across labella Insulins hear an 80% growth on the year. You know we're really pleased it is the most successful launch in history. As we've mentioned it's also now the fourth largest product for.
Speaker Change: Combined the three major franchise areas and we're calling double digit growth across those as you've seen in the <unk>. Even after three years in the market outside the U S and in Europe we.
Erin Wright: Or is the wettest with 25 million doses.
Erin Wright: 40% of dogs suffer from OE and what we really see as we look forward is continued growth in this category. We did get a the dear Doc letter, which helps best understand what the update in adverse events were.
Speaker Change: We delivered 33% growth.
Speaker Change: Well in the third year. So we are expecting annual growth to be strong to robust across these franchises across the OA pain as we go forward, even if we're not giving specific guidance on individual products on margins. You are right MSA divestiture is accretive to our gross margins and our bottom line margins as well in addition to that we have mix as <unk>.
Erin Wright: Real World data and we obviously.
Erin Wright: Showed you the label that we implemented based on that and I think that really underscores our commitment for transparency, which we've been doing all along with regard to the adverse events.
Erin Wright: I would highlight that there were no contraindications no warnings and no precautions in that label, but we were really pleased to be able to share that with veterinarians consistent with our purpose and consistent with our commitment anything veterinarians have found that quite helpful that label as we had mentioned to you. Many times is we expected it to be consistent with our label and international where we continue.
Speaker Change: We see more of our growth driven by our companion animal.
Speaker Change: Products that drive favorable mix for us from a margin standpoint, as well and from a price as we've said consistently.
Speaker Change: We are expecting to see price to be above the two to three that we've typically done historically, but below the 6% with it this year or nearly five we did the prior year part of that is lower contribution from some of these hyper inflationary markets that we saw in the prior year is why you see that but still we're taking price and therefore, that's contributing to our margins.
Erin Wright: To be driving growth as you saw throughout 2024 to the U S label look largely like a label in Europe, or Canada, and we really look forward to continuing to grow. This franchise. What made you want to take the second question on margin sure before I get to the margin maybe just one more point I'll make on the <unk> you asked about how we factored that into our guidance clearly.
Speaker Change: One of the offsets as we've seen with the U S dollar strength over the last number of years is FX and we do see that being an offset in addition to increased manufacturing costs that we have but net net.
Erin Wright: Combined the three major franchise areas and we're calling double digit growth across those as you've seen in labella, even after three years in the market outside the U S and in Europe we.
Speaker Change: And on the FX side, it's about 50 basis points headwind at the gross margin level.
Erin Wright: We delivered 33% growth.
Speaker Change: Thank you we'll take our next question from Jon Block with Stifel. Please go ahead.
Erin Wright: The gorilla in the third year. So we are expecting annual growth to be strong through robust across these franchises across the OA pain as we go forward, even if you're not giving specific guidance.
Jon Block: Thanks, guys good morning.
Jon Block: Just what are your thoughts on the revenue cadence for 2025 arguably competition will pick up in some key areas you called it out but that's more back part.
Erin Wright: Individual product on margins you are right MFA divestiture is accretive to our gross margins and our bottom line margins as well. In addition to that we have mix as we see more of our growth driven by our companion animal.
Jon Block: Of the year, you got arguably an easy comp in the fourth quarter.
Jon Block: So curious on the cadence and then just for R&D flat year over year, you walked through some of that is this sort of a new beginning for you guys, where this can be considered a more leverage will call line item going forward. Thanks.
Erin Wright: Products that drive favorable mix for us from a margin standpoint, as well and from a price as we've said consistently.
Erin Wright: We are expecting to see priced above the two to three that we've typically done historically, but below the 6% with it this year or nearly five we did the prior year part of that is lower contribution from some of these hyper inflationary markets that we saw in the prior year.
Jon Block: Yeah. So John first on the revenue cadence is that as I mentioned.
Jon Block: The most important aspect here is we look at the trends that are driving our business and demand across our products and the momentum we had in 2024, we see that entering into 2025, so that gives us confidence and that's baked into our guidance here as I said on the earlier question. We are factoring a number of scenarios around new entrants.
Erin Wright: You see that but still we're taking price and therefore that is contributing to our margins one of the offsets as we've seen with the U S. Dollar strength over the last number of years is FX and we do see that being an offset in addition to increased manufacturing costs that we have but net net on the FX side, it's about 50 basis points headwind at the gross margin level.
Jon Block: That may come in and those are more more so on the back half of the year. So that would imply a stronger first versus versus versus second half I wouldn't necessarily call out an easy comp in Q4 from an organic operational perspective, maybe for a.
Moderator: Thank you we'll take our next question from Jon Block with Stifel. Please go ahead.
Jon Block: Reported perspective, given the divestiture of MSA as I said in the prepared commentary when you factor out the MSA, it's a 9% operational growth organic operational growth quarter for us and then we had the comps.
Jon Block: Thanks, guys good morning.
Jon Block: Just wondering any thoughts on the revenue cadence for 2025 arguably competition will pick up in some key areas you called it out but that's more back part.
Jon Block: Of the year, you got arguably an easy comp in the fourth quarter.
Jon Block: From the prior year, where we launched roughly Guilla in Africa through in the fourth quarter of the prior year when you add that into consideration the growth in the fourth quarter is above 10% and so I think that's a that's a.
Jon Block: So curious on the cadence and then just for R&D flat year over year, you walked through some of that is this sort of a new beginning for you guys, where this can be considered a more leverage will call line item going forward. Thanks.
Solid quarter, and I wouldn't call that an easy commentary as you look at 2020 five in terms of R&D look we're very pleased with the progress that we're seeing across the pipeline and we showcase those with the update we provided last month at the Jpmorgan conference. We tend to let the pipeline drive where the investment is and not necessarily.
Jon Block: Yeah, So John first on the revenue cadence as I've mentioned.
Jon Block: The most important aspect here is we look at the trends that are driving our business and demand across our products and the momentum we had in 2024, we see that entering into 2025, so that gives us a lot.
Jon Block: Deliberately drive that is it leverages both components now we did see two years ago almost at Investor Day, we expected the R&D line to grow above revenue for some time now.
Jon Block: Covenant net baked into our guidance here as I said on the earlier question. We are factoring in a number of scenarios around new entrant that may come in and those are more forceful in the back half of the year. So that would imply a stronger first versus versus versus second half I wouldn't necessarily call out an easy comp.
Jon Block: Sort of move back towards.
Jon Block: Top line revenue growth rate and we're seeing that but I think that's more of a factor of where the pipeline is certainly as major items go through certain cycles in development. They tend to drive more spend and then as they get on the other side of that it's not as much so that will ebb and flow from time to time, but we don't look at that necessarily as it leverages <unk> line item.
Jon Block: In Q4 from an organic operational perspective, maybe flaw.
Jon Block: 40 perspective, given the divestiture of MSA as I've said in the prepared commentary when you factor out the MSA is a 9% operational growth organic operational growth quarter for us and then we had the comps.
Jon Block: There were deliberately moving because the long term delivery of innovation, all drives where we drive investments there.
Jon Block: Thank you we'll take our next question from Brian and Vasquez with William Blair. Please go ahead.
Jon Block: From the prior year, where we launched roughly Wella in Africa through in the fourth one of the prior year when you add that into consideration the growth in the fourth quarter is above 10% and so I think that's a that's a solid quarter and I wouldn't call that an easy comp as short as we look at 2020 five in terms of R&D look we're very pleased with the progress that we're seeing across the <unk>.
Speaker Change: Hi, This is Russell you in on for Brandon Vazquez. Thanks for taking the question so.
Speaker Change: So looking at a high level are you guys. It will to give us any sense as we go into 2025 and how the entire pet population is kind of trending now.
Speaker Change: Now that we're past couple of years are we back to normal growth rates and growing year over year or if not is there anything that you kind of need to keep in mind for the backdrop to get a normalized growth rate.
Jon Block: Pipeline and we showcased those with the update we provided last month at the Jpmorgan Conference. We tend to lead the pipeline drive where the investment is not necessarily deliberately drive that is the leverage component now we did see two years ago almost at Investor day, we expected the R&D line to grow above revenue.
Speaker Change: I know, we sometimes hear about a lagging effect from weak macro where pets are not replacement or they die. So kind of just curious on what you're seeing thanks.
Speaker Change: Sure what we can.
Speaker Change: Continue to see is the strength of the human animal bond and that relationship and if you look back at historical numbers normally theres not significant changes in the number of pets, they're the only one section obviously in the last 12 years was COVID-19.
Jon Block: For some time then.
Jon Block: Sort of move back towards.
Jon Block: Sort of top line revenue growth rate and we're seeing that but I think that's more of a factor of where the pipeline is certainly has major items go through certain cycles in development. They tend to drive more spend and then as they get on the other side of that it's not as much so that will ebb and flow from time to time, but we don't look at that necessarily as it leverages <unk> line item.
Speaker Change: We're expecting the pet population to remain relatively stable. That's what it's done historically I think what's really changed and what's driving the fundamental growth of the industry is the fact that the human animal bond. It makes animal health essential and very resilient, 86% of pet owners would spend whatever it takes and those incremental tests that were adopted.
Jon Block: There were deliberately moving because the long term delivery of innovation.
Jon Block: Drives where we drive investments there.
Speaker Change: Thank you we'll take our next question from Brian <unk> with William Blair. Please go ahead.
Speaker Change: During a COVID-19 are aging and as they age they're gonna get more diseases of chronic.
Speaker Change: Chronic diseases et cetera, so we see very strong fundamental drivers with more millennials and Gen Z adopting pets their relationship with those pets that are delaying having kids that they're having kids and those pads are important parts of their families life and they're making sure that those pets are taken care of so we see very strong growth drivers based on the human animal bond baked into the <unk>.
Hi, This is Russell you in on for Brandon Vazquez, Thanks for taking the questions.
Speaker Change: So looking at a high level are you guys. It will take give us any sense as we go into 2025 and how the entire pet population is kind of trending now.
Speaker Change: Now that we're past couple of years are we back to normal growth rates and growing year over year or if not is there anything where you kind of need to keep in mind for the backdrop to get a normalized growth rate.
Speaker Change: Wrapping their pets as well as an aging population. So we think those are fundamental drivers that the way. This is innovation and commercial excellence will only emphasize more.
Speaker Change: I know, we sometimes hear about a lagging effect from weak macro where pets are not replace those or they die. So kind of just curious on what you're seeing thanks.
Thank you we'll take our next question from <unk> Prasad with Barclays. Please go ahead.
Speaker Change: Sure what we continue to see is the strength of the human animal bond and that relationship and if you look back at historical numbers normally theres not significant changes in the number of pets, they're the only one section obviously in the last 12 years with Covid.
Prasad: Hi, Good morning couple of questions for me Firstly, let me clarify that none of the expecting approvals within the next 12 months have been factored into the guidance curious to understand it.
Prasad: Maybe excluding FX what are the upside risk to guidance that you can see from here and on the same line of the three buckets of approvals of drivers as Ken described that phone.
Speaker Change: But we're expecting the pet population to remain relatively stable. That's what it's done historically I think what's really changed and what's driving the fundamental growth of the industry is the fact that the human animal bond it makes animal health.
Prasad: Is there any way to quantify the.
Speaker Change: Essential and very resilient ATC.
Prasad: Approval of <unk> in the second bucket in the 12 to 36 months and what the Tam for these approvals are and what are the investments into those tanks.
Speaker Change: 86% of pet owners would spend whatever it takes and those incremental tests that were adopted.
Speaker Change: During a COVID-19 are aging and as they age they are going to get more diseases.
Prasad: Sure sure.
Prasad: Look in terms of confirming that we have not factored in new approvals and that's consistent with how we've approached guidance. Historically so those are not in here. We did highlight how much FX headwind, we see at the top line roughly $250 million, given where spot rates are and as a reminder, we do not forecast FX. So the.
Speaker Change: Chronic diseases et cetera, we see very strong fundamental drivers with more millennials and Gen Z adopting pets their relationship with those pass they are delaying having kids that they're having kids and those pets are important parts of their families life and they are making sure that those pets are taken care of so we see very strong growth drivers based on the human animal bond baked into the <unk>.
Prasad: Quantification, we're providing is strictly off of the current spot rates versus what the average rates were through 2024 in terms of upside look I think we have a very diverse portfolio and a diversity central cross geography across our products et cetera, you saw us deliver across our three major franchises and companion.
Speaker Change: Their pets as well as an aging population. So we think those are fundamental drivers that the way. This is innovation and commercial excellence will only emphasize more.
Speaker Change: Thank you we'll take our next question from velocity <unk> Prasad with Barclays. Please go ahead.
Prasad: Hi, Good morning couple of questions from me Firstly, let me clarify that none will be expecting approvals within the next 12 months have been factored into the guidance curious to understand.
Prasad: Animal all three had double digit growth and double digit growth in terms of volumes as well. So I think the underlying trends here are strong as we enter into 2025 and we couldn't be more pleased of course, there are factors that we put in in terms of where competitive interests might come in could be a factor that might move us.
Prasad: Maybe excluding FX what are the upside risk to guidance that you can see from here and on the same line of the three buckets of approvals of drivers as you can describe that for them.
Prasad: Any direction in terms of the timing of those.
Prasad: Is there any way to quantify the.
Prasad: What some of the short term sort.
Prasad: Approval is old enough in the second bucket in the 12 to 36 months and what the Tam for these approvals are on one of the investments into those tanks.
Prasad: So the dynamics might be around around those and those are the things that might that might move us one way or the other which is why we provided a range in our guidance, but we're very very excited about how we're entering the year and the demand profile that we're seeing across our products and the opportunities we have before us.
Prasad: Sure sure.
Prasad: Look in terms of confirming that we have not factored in new approvals and that's consistent with how we've approached guidance. Historically so those are not in here. We did highlight how much FX headwind, we see at the top line roughly $250 million, given where spot rates are and as a reminder, we do not forecast FX. So the.
Prasad: I can pick up the second question on the Tam for the new product categories. I mean, I wanted to start with we have more drivers of growth to improve the standard of care than any other company and we as we've talked about in our pipeline we have multiple blockbusters in a J P. Morgan we discussed what the total addressable market for some of these new therapies would be to your point in.
Prasad: Quantification, we're providing strictly off of the current spot rates versus what the average rates were through 2024 in terms of upside look I think we have a very diverse portfolio and our diversity across geography across our products et cetera, you saw us deliver across our three major franchises and companion.
Prasad: 12 to 36 month window, we have chronic kidney disease product and as we mentioned that's a $3 billion to $4 billion market and we also mentioned oncology and that's a one 2% to $1 7 billion dollar market and then in the longer term. We were also talking about cardiology I also just wanted to double click for a second on the long acting portfolio.
Prasad: Animal all three had double digit growth and double digit growth in terms of volumes as well. So I think the underlying trends here are strong as we enter into 2025 and couldn't be more pleased of course, there are factors that we put in in terms of where competitive interests might come in could be a factor that might move us.
Prasad: Because I really think these are going to be significant growth drivers. There's a lot of people who can make it in every month's a little increased compliance, which will grow the market as well as meet a lot of our pet owners, who just the monthly is too much for them and they would be much more convenient to come in four times a year versus 12 times a year. So we really think if you look at you know potential approvals approval.
Prasad: Any direction in terms of the timing of those.
Prasad: What some of the short term sort.
Prasad: So the dynamics might be around around those and those are the things that might that might move us one way or the other which is why we provided a range in our guidance, but we're very very excited about how we're entering the year and the demand profile that we're seeing across audits and the opportunities we have before us.
Prasad: Every year for the next several years and really more drivers of growth for the short medium and long term for the company. We remain really excited about the potential unmet needs that we can address.
Chris Schott: Thank you we'll take our next question from Chris Schott with Jpmorgan. Please go ahead.
Prasad: I can pick up the second question on.
The Tam for the new product categories, I mean, I wanted to start with we have more drivers of growth to improve the standard of care than any other company and we as we talked about in our pipeline we have multiple blockbusters in a J P. Morgan we discussed what the total addressable market for some of these new therapies would be to your point in the 12 to 36 month window.
Chris Schott: Oh, great. Thanks, so much for the questions just two for me first on <unk> is there any updates in terms of how youre seeing veterinarians approach patient selection is thinking about severe patients versus moderate is it is it still skewed more towards severe or you start to make progress on the moderate side and the second question was on <unk> trio.
Prasad: We have chronic kidney disease product and as we mentioned, that's a $3 billion to $4 billion market and we also mentioned oncology and that's a one two to $1 7 billion dollar market and then in the longer term. We were also talking about cardiology I also just wanted to double click for a second on the long acting portfolio because I really think these are going to be significant.
Chris Schott: Obviously very healthy growth in 2024, just any pushes and pulls we should think about for that product specifically in 25. Thank you.
Chris Schott: Sure with regards to Libra.
Chris Schott: We continue to see in Europe more of our patients be mild.
Mild to moderate and that trend has continued in the U S. The beginning part of the launch we were seeing more severe they are moving more into moderate again, you got to know the product better so that will be a key focus of the growth in the U S. As we move more into the moderate patients. You know we continue to do blind studies with veterinarians and they continue to be very satisfied.
Speaker Change: Both drivers there's a lot of people who can make it in every month's a little increased compliance, which will grow the market as well as meet a lot of our pet owners, who just the monthly is too much for them and they would be much more convenient to come in four times, a year versus 12 times a year and so we really think if you look at you know potential approvals approval every year for the next several years and really more.
Chris Schott: With the product.
Chris Schott: They continue to intend to prescribe and I think the more we do and get those into moderate patients. We'll see continued growth there with regard to assumptions in trio, we had a phenomenal a process of Paragon franchise year trio is now.
Speaker Change: More drivers of growth for the short medium and long term for the company. We remain really excited about the potential unmet needs that we can address.
Speaker Change: Thank you we'll take our next question from Chris Schott with Jpmorgan. Please go ahead.
Chris Schott: Exceeding $1 billion on it is the number one seller in the U S and it's been on the market for years, even with significant competition.
Chris Schott: Oh, great. Thanks, so much for the questions just two for me first on Labella is there any updates in terms of how youre seeing veterinarians approach patient selection as you think about severe patients versus moderate is it is it still skewed more towards severe or you are you starting to make progress on the moderate side and the second question was on <unk>.
Chris Schott: We saw about a 28% growth I think it was important to really remind people is there is still significant growth in this category today, we got 50% of puppies, which means 50% of puppies are still not on a triple combination we think that will continue to grow the market.
Chris Schott: Obviously very healthy growth in 2024, just any pushes and pulls we should think about for that product specifically in 25. Thank you.
We think also as you add more and more people on auto ship. Once you started parasiticide, you're very unlikely to switch. So this is a very sticky categories and even if we see new competition. We continue to believe just as we did when we thought.
Chris Schott: Sure with regards to Libra.
Chris Schott: We continue to see in Europe more of our patients be mild.
Chris Schott: Mild to moderate and that that trend has continued in the U S. The beginning part of the launch we're seeing more severe they are moving more into moderate again, you got to know the product better so that will be a key focus of the growth in the U S.
Chris Schott: Enter and we can continue to grow this market and grow our share and I think we continue to demonstrate our ability to do that.
Speaker Change: Thank you we'll take our next question from Glenn <unk> with Jefferies. Please go ahead.
Chris Schott: Let me move more into the moderate patients.
Speaker Change: Hi, yes, thanks for taking my question.
Chris Schott: We continue to do blind studies with veterinarians and they continue to be very satisfied with the product.
Speaker Change: Just wanted to follow up on some of the comments you made with respect to the organic growth. If you look at the sort of pricing expectation you're building into your assumption. This year I think you said it would be better than your 2% to 3% normalized expectation, so with sort of half of the operational growth coming from pricing. It seems like you're assuming some modest.
Chris Schott: And they can continue to intend to prescribe and I think the more we do and get into moderate patients. We'll see continued growth there with regard to assumptions in trio, we had a phenomenal a process compared to franchise year trio is now.
Chris Schott: Exceeding $1 billion on it is the number one seller in the U S and it's been on the market for years, even with significant competition.
Speaker Change: Slowdown on the volume side, and just sort of given that you expect significant double digit growth in your three major franchise I guess, maybe talk about if either you or Christian can you talk about maybe some of the other areas of the portfolio, where you may be seeing some levels of deceleration in volume and maybe that shows.
Chris Schott: We saw about a 28% growth I think it was important to really remind people is there are still significant growth in this category. Today, you know, we got 50% of puppies, which means 50% of puppies are still not on a triple combination we think that will continue to grow the market.
Speaker Change: Some level of conservatism you're building into your guidance.
Speaker Change: Sure happy happy to do that as I said, our pricing expectations for 2025 or a bit north of our historical two to three but below the 6% we printed in 2024 and roughly four 5% to 5%. The prior few years. So that is certainly a consideration one other thing I'll remind you is we saw a livestock growth.
Chris Schott: We think also as you have more and more people on auto ship. Once you started parasiticide, you're very unlikely to switch. So this is a very sticky categories and even if we see new competition. We continue to believe just as we did when we thought.
Chris Schott: Enter and we can continue to grow this market and grow our share and I think we continue to demonstrate our ability to do that.
In 2024 at a roughly 5%.
Speaker Change: Thank you we'll take our next question from Glenn <unk> with Jefferies. Please go ahead.
Speaker Change: And if you take the MFA divestiture out it's actually 6% on 2024, we are calling two to four which is what the industry growth rate is from a lifestyle standpoint, again I will repeat this point, which is really really important the underlying trends that we see driving demand for our products are entering into 2025, and so that gives us a lot of confidence.
Glenn: Hi, yes, thanks for taking my question.
Speaker Change: Just wanted to follow up on some of the comments you made with respect to the organic growth. If you look at the sort of pricing expectations you're building into your assumption. This year I think you said it'll be better than your 2% to 3% normalized expectation, so with sort of half of the operational growth coming from pricing. It seems like you're assuming some modest.
Speaker Change: Going to see we saw double digit volume growth across these major franchises in 2024.
Speaker Change: Our factoring certain competition in there and so depending on how you look at the range of six to eight.
Slow down on the volume side, and just sort of given that you.
Speaker Change: You expect significant double digit growth in your three major franchises I guess, maybe talk about if either you or Christian can you talk about maybe some of the other areas of the portfolio, where you may be seeing some levels of deceleration in volume and maybe that shows.
Speaker Change: Taking what I am saying on price at the low end of the range. Yes, you would have slightly more price than volume at the heart of the range you would actually have a balance between price and volume, which is what you saw from us excluding hyperinflationary markets as 2024, so that feels about the same as what we're seeing in 2025, depending on where you fall in the range that we're hitting our guidance.
Speaker Change: Some level of conservatism you're building into your guidance. Thanks.
Speaker Change: Sure happy happy to do that as I said, our pricing expectations for 2025 or a bit north of our historical two to three but below the 6% we printed in 2024 and roughly four 5% to 5%. The prior few years. So that is certainly a consideration one other thing I'll remind you is we saw livestock growth.
Speaker Change: Thank you we'll take our next question from.
Speaker Change: Nevada tie with BNP Paribas. Please go ahead.
Speaker Change: Hi, good morning.
Speaker Change: Two questions. Please the first one on labor at all if you can discuss any expected impact of the U S label changes if any on the transition to the moderate population in the U S. And then my second question is on innovation. If you can comment on the blockbuster potential of the bank.
Speaker Change: In 2024 at a roughly 5%.
Speaker Change: And if you take the MFA divestiture out it's actually 6% on 2020, what we are calling two to four which is what the industry growth rate is from a lifestyle standpoint, again I will repeat this point, which is really really important the underlying trends that we see driving demand for our products are entering into 2025, and so that gives us a lot of confidence.
Speaker Change: Thank you for the pools that you have listed thank you.
Speaker Change: Sure.
Speaker Change: We were very pleased to implement the new label, we think it helps us to understand the latest data on real world adverse events, we continue to be incredibly transparent throughout with regards to what we were seeing in other markets and we shared that data. So we really see this as just helping them better understand it's consistent with what we have been sharing with.
Speaker Change: I'm going to see we saw double digit volume growth across these major franchises in 2024.
Speaker Change: Factoring certain competition in there and so depending on how you look at the range of six to eight.
Speaker Change: It's taking what I'm, saying on price at the low end of the range. Yes, you would have slightly more price and volume and the higher hazard ratio would actually have a balance between price and volume, which is what you saw from us excluding hyperinflationary markets was 124, so that feels about the same as what we're seeing in 2025, depending on where you fall in the range that we're providing.
Speaker Change: All along so we don't really think it changes the trajectory much we think what we're seeing in the U S is more moderate patients and continuing to grow that market and as I mentioned before the surveys were doing was that they are satisfied with the product and they continue to have an intent to prescribe what we're really seeing is just the impact is making on improving the quality.
Speaker Change: Okay.
Speaker Change: Of life for so many pets. So we really see continued growth overall in that and with your second question on the multiple blockbusters, we're really seeing as we talked about that total addressable market for some of these new unmet needs being very significant you know the one I'd really focus on the largest is obviously chronic kidney disease, that's both for <unk>.
Speaker Change: Thank you we'll take our next question from.
Speaker Change: Suzanne tie with BNP Paribas. Please go ahead.
Speaker Change: Hi, good morning too.
Two questions. Please the first one on Libre, if you can discuss any expected impact of the U S label changes if any on the transition to the moderate population in the U S. And then my second question is on innovation. If you can comment on the blockbuster potential of the.
Speaker Change: <unk> and per cap and there really are no treatments today, and we expanded the size of the total addressable market from our Investor day, and that was really into that better understanding the molecules that we have today.
Speaker Change: Expected approvals that you have listed thank you.
Speaker Change: And really how theyre going to meet that unmet medical need, but also importantly increases and improvements in diagnostics to be able to better diagnose animals to make sure that we're getting the right patient population aligned with the potential of the product. So we're very excited as we look at chronic kidney disease oncology as well as cardiology.
Speaker Change: Sure.
Speaker Change: We were very pleased to implement the new label, we think it helps us to understand the latest data on real world adverse events, we continue to be incredibly transparent.
Speaker Change: With regards to what we were seeing in other markets and we shared that data. So we really see this as just helping them better understand it's consistent with what we have been sharing with them. All along so we don't really think it changes the trajectory much we think what we're seeing in the U S is more moderate patients and continuing to grow that market and as I mentioned before the surveys were doing with that they're satish.
Speaker Change: It really meet new unmet medical needs of the market has really been looking at and as I mentioned before have more drivers of growth for the short medium and long term to improve the standard of care.
Steve Scala: Thank you we'll take our next question from Steve Scala with TD Securities. Please go ahead.
Speaker Change: With the product and they continue have an intent to prescribe what we're really seeing is just the impact is making on improving the quality.
Chris Schott: Thank you this is Chris <unk> Arthur Steve Scala, We just had a question on the pipeline Mr. Justin the pipeline opportunities.
Speaker Change: Of life for so many pets. So we really see continued growth overall in that and with your second question on the multiple blockbuster, we're really seeing as we talked about that total addressable market for some of these new unmet needs being very significant you know the one I'd really focus on the largest is obviously chronic kidney disease, that's both for <unk>.
Apologies.
Chris Schott: Assets generated pivotal data yet in terms of what does have multiple shots on goal multiple late stage assets.
Chris Schott: Each of these opportunities and to these plants be placed at a premium to bedroom additions to the paint Fedex. Thank you.
Speaker Change: Sure, we don't give specific information with regard to our molecules on animal health. So the guidance that we provided with regards to product launching is the guidance that we've got.
Speaker Change: And for Cat and there really are no treatments today, and we expanded the size of the total addressable market from our Investor day, and that was really into that better understanding the molecules that we have today.
Speaker Change: Okay. We will go next to Andrew Alfonzo with UBS. Please go ahead.
Speaker Change: And really how theyre going to meet that unmet medical need, but also importantly increases and improvements in diagnostics to be able to better diagnose animal to make sure that we're getting the right patient population to align with the potential of the product. So we're very excited as we look at chronic kidney disease oncology as well as a cardiology to.
Andrew Alfonzo: Yes, hi, good morning. Thank you so much for taking my question.
Andrew Alfonzo: Specifically wanted to ask about the dermatology franchise and how you're thinking about your positioning in 2025 for me pricing versus mix standpoint in light of competitive entries and have you had to amplify some of your education and awareness efforts around efficacy relatively.
Speaker Change: Really neat new unmet medical needs of the market has really been looking at and as I mentioned before have more drivers of growth for the short medium and long term to improve the standard of care.
And then I guess finally, when is sort of your view on kind of the mix shift between <unk> and Apple. Thank you so much.
Steve Scala: Thank you we'll take our next question from Steve Scala with TD Securities. Please go ahead.
Andrew Alfonzo: Sure.
Andrew Alfonzo: Very excited for the performance of dermatology in 2024, with 17% growth with a $164 billion portfolio importantly, even with competition in Q4, we had 11% revenue growth and we really are seeing growth in this market overall I think Whitney managed mentioned in his remarks before we're seeing that market.
Chris Schott: Thank you this is Chris won't be until after Steve Scala, We just had a question on the pipeline Mr. Justin the pipeline opportunities.
Speaker Change: Apology at these assets generated pivotal data yet in terms of what does have multiple shots on goal multiple late stage assets.
Speaker Change: Each of these opportunities and could this product be placed at a premium compared to so let us as Colin Denman paint Fedex. Thank you.
Andrew Alfonzo: Grow 11%, we think by 2028, it will grow to $2 5 billion and there are 20 million dogs that still remain untreated or under treated then we can still focus on so we see growth here in a few areas first higher compliance getting more animals on auto ship.
Speaker Change: Sure, we don't give specific information with regard to our molecules on animal health. So the guidance that we provided with regards to product launching is is the guidance that we've got.
Speaker Change: Okay. We'll go next to Andrea Alfonso with UBS. Please go ahead.
Andrew Alfonzo: Obviously looking at long acting portfolio coming as well, we see that as potentially improving compliance and really going.
Andrea Alfonso: Yes, hi, good morning. Thank you so much for taking my question.
Andrew Alfonzo: Going after the Undertreated dogs today as well as the untreated adults. So we see significant continued growth here for the overall market, even with competition and what we continue to see in other franchises and in other categories. It is new competition, you have new awareness and we continue to grow the category overall.
Andrea Alfonso: I, specifically wanted to ask about the dermatology franchise, and how youre thinking about.
Andrea Alfonso: Positioning in 2025 for me pricing versus mix standpoint in light of competitive entries and have you had to amplify some of your education and awareness efforts around efficacy relatively.
Andrew Alfonzo: I'll just I'll just add from a pricing standpoint, we don't provide product specific pricing considerations, but I would remind you in 2024, we saw 17% operational growth and double digit volume growth. Despite robust price here. So we do believe there's opportunity given the remaining untreated pet.
Andrea Alfonso: And then I guess finally, when is sort of your view on kind of the mix shift between <unk> and Apple Paul. Thank you so much.
Andrea Alfonso: Sure.
Andrea Alfonso: After the performance of dermatology in 2024, with 17% growth with a $164 billion portfolio importantly, even with competition in Q4, we had 11% revenue growth and we really are seeing growth in this market overall I think when he managed mentioned in his remarks before we're seeing that market.
Andrew Alfonzo: Pets in this space and opportunity to continue to grow in terms of the balance look we see strong demand for both products. If you look at <unk> and Apple coil side a point in the clinic is preferred both from a compliance standpoint, and having then the volume through the clinic I think well in alternative channels. When you combine both retail and home delivery.
Andrea Alfonso: ROE of 11%, we think by 2028, it will grow to $2 5 billion and there are 20 million dogs that still remain untreated or under treated that we can still focused on so we see growth here in a few areas first higher compliance getting more animals on auto ship.
Andrew Alfonzo: That total is about 40% of our Africa volume and you've seen that convenience factor the compliance of their drive to drive significant growth as well. So a 24, we actually saw a balanced growth between the two is which is very very encouraging as we go into 2025.
Andrea Alfonso: Obviously looking at long acting portfolio coming as well, we see that as potentially improving compliance and really going after the undertreated dog today as well as the untreated dogs. So we see significant continued growth here for the overall market, even with competition and what we continue to see in other franchises and in other categories.
Daniel Clark: Thank you we'll go next to Daniel Clark with Leerink Partners. Please go ahead.
Daniel Clark: Great. Thank you just wanted to drill down a little bit on figuring that 50% of puppies are a triple combo parasiticide what are the different pushes and pulls that you think could maybe drive that number higher and how are you thinking about that for 2025.
Andrea Alfonso: New competition, you have new awareness and we continue to grow the category overall I'll just I'll just add from a pricing standpoint, we don't provide product specific pricing considerations, but I would remind you in 2024, we saw 17% operational growth and double digit volume growth. Despite robust price here. So we do believe there's opportunity given the.
Daniel Clark: Sure again, we think awareness and growth if you look at it right now the triple combination therapy still is less than 40% overall and it's growing at 40%. So we think that you will continue to be the more you add any puppies the more they are on it and once they go on their very unlikely to go up. So we really are excited to see this growth and.
Andrea Alfonso: The remaining untreated.
Andrea Alfonso: Pets in this space and opportunity to continue to grow in terms of the balance look we see strong demand for both products. If you look inside of <unk> and <unk> in the clinic is preferred both from a compliance standpoint and having that.
Daniel Clark: We continue to see as new entrants enter it only brings more attention to triple combinations, which is the fastest growing segment of parasiticide overall and the triple market today is $2 billion and we're expecting as we mentioned before to grow to $4 $5 billion by 2028. So we just see the natural growth here and you know as someone who as you know.
Andrea Alfonso: All of them to the clinic I think well in alternative channels. When you combined both retail and home delivery that total is about 40% of our Africa volume and you've seen that convenience factor the compliance of their drive to drive significant growth as well. So the 24, we actually saw a balanced growth between the two.
Daniel Clark: First day here, we've had for years and it's an additional three years on the market ahead of anybody else, we see really that lead making a big difference and continuing to grow our share and to grow the market overall.
Andrea Alfonso: <unk> is which is very very encouraging as we go into 2025.
Daniel Clark: And there are no further questions at this time I will turn it to Christian for closing remarks.
Speaker Change: Thank you we'll go next to Daniel Karp with Leerink partners. Please go ahead.
Christian: Okay, great as always thank you everyone for your questions and importantly for your continued interest in <unk>.
Great. Thank you just wanted to drill down a little bit on figuring that 50% of puppies are a triple combo parasiticide what are the different pushes and pulls that you think could maybe drive that number higher and how are you thinking about that for 2025.
Christian: As you heard today, we are extremely pleased with our excellent performance in 2024 and eager to really build on this momentum as we move into 2025, we remain confident in the steady demand for our diverse and our innovative portfolio, which continues to deliver value to our customers and to advance animal health globally and were driven by our purpose to advance care for animals.
Speaker Change: Sure again, we think awareness and growth if you look at it right now the triple combination therapy still is less than 40% overall and it's growing at 40% that we think that you will continue to be the more you add new puppies the more they're on and once they go on their very unlikely to go up. So we really are excited to see this growth and what we can.
Christian: And we remain focused on executing our strategy instilling confidence in our stakeholders and reinforcing our unwavering commitment to our value proposition. We look forward to keep you update on our progress as the year progresses. Thanks everybody.
Speaker Change: To see as new entrants enter it only brings more attention to triple combinations, which is the fastest growing segment of parasiticide overall and the triple market today is $2 billion and we're expecting as we mentioned before to grow to $4 $5 billion by 2028. So we just see the natural growth here and you know as someone who is.
Christian: Thank you. This does conclude today's program. Thank you for your participation you may disconnect at any time.
Speaker Change: First day here, we've had for years and an additional three years on the market ahead of anybody else, we see really that lead making a big difference and continuing to grow our share and to grow the market overall.
Speaker Change: Yeah.
Christian: And there are no further questions at this time I will turn it to Christian for closing remarks.
Christian: Okay, great as always thank you everyone for your questions and importantly for your continued interest in <unk>.
Christian: As you heard today, we are extremely pleased with our excellent performance in 2024 and eager to really build on this momentum as we move into 2025, we remain confident in the steady demand for our diverse and our innovative portfolio, which continues to deliver value to our customers and to advance animal health globally and were driven by our purpose to advance care for animals.
Christian: And we remain focused on executing our strategy instilling confidence in our stakeholders and reinforcing our unwavering commitment to our value proposition. We look forward to keep you update on our progress as the year progresses. Thanks everybody.
Christian: Thank you. This does conclude today's program. Thank you for your participation and you may disconnect at anytime.
Christian: Yeah.
Christian: [music].